Protagonist Therapeutics (NASDAQ:PTGX) Stock Dropped to “Buy” by Wall Street Zen

Wall Street Zen downgraded shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) from a strong-buy rating to a buy rating in a research report released on Sunday morning,Wall Street Zen reports.

PTGX has been the topic of several other research reports. Wolfe Research reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research note on Monday, August 31st. Weiss Ratings upgraded Protagonist Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, November 4th. UBS Group reissued a “buy” rating on shares of Protagonist Therapeutics in a research report on Tuesday, November 3rd. Barclays upped their price target on shares of Protagonist Therapeutics from $153.00 to $180.00 and gave the company an “overweight” rating in a report on Tuesday, September 1st. Finally, Zacks Research raised Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating and sixteen have assigned a Buy rating to the stock. Based on data from MarketBeat, Protagonist Therapeutics has a consensus rating of “Buy” and a consensus price target of $166.67.

Read Our Latest Research Report on Protagonist Therapeutics

Protagonist Therapeutics Stock Performance

Shares of Protagonist Therapeutics stock opened at $130.95 on Friday. The company’s 50-day moving average price is $140.30 and its two-hundred day moving average price is $119.11. Protagonist Therapeutics has a 52 week low of $77.00 and a 52 week high of $160.81. The stock has a market cap of $8.55 billion, a PE ratio of 27.74 and a beta of 1.21.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $3.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.57. Protagonist Therapeutics had a net margin of 62.04% and a return on equity of 42.83%. The company had revenue of $274.41 million during the quarter, compared to the consensus estimate of $238.49 million. On average, equities analysts predict that Protagonist Therapeutics will post 5.52 EPS for the current fiscal year.

Insider Transactions at Protagonist Therapeutics

In other news, CFO Asif Ali sold 58,629 shares of the company’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $141.78, for a total transaction of $8,312,419.62. Following the completion of the transaction, the chief financial officer owned 59,003 shares of the company’s stock, valued at approximately $8,365,445.34. This represents a 49.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinsesh Patel sold 63,548 shares of the stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $146.18, for a total transaction of $9,289,446.64. Following the completion of the sale, the chief executive officer owned 522,968 shares of the company’s stock, valued at approximately $76,447,462.24. The trade was a 10.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 183,629 shares of company stock valued at $26,552,987 in the last ninety days. 5.19% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Protagonist Therapeutics during the 2nd quarter worth approximately $1,263,535,000. Johnson & Johnson bought a new stake in Protagonist Therapeutics in the second quarter valued at $300,220,852. Jupiter Topco LLC bought a new stake in Protagonist Therapeutics in the second quarter valued at $261,039,000. Bank of America Corp DE bought a new stake in Protagonist Therapeutics in the second quarter valued at $162,357,000. Finally, ADAR1 Capital Management LLC acquired a new position in Protagonist Therapeutics during the second quarter worth $117,783,000. 98.63% of the stock is currently owned by institutional investors and hedge funds.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Recommended Stories

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.